Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) --

以色列拉阿纳纳，2025年4月2日（环球新闻社）--

Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide..

Polyrizon Ltd.（纳斯达克股票代码：PLRZ），一家专注于创新鼻腔水凝胶的生物技术公司，今天宣布已与一家全球知名的品牌和商标咨询公司达成协议，该公司以与全球领先的制药和医疗器械公司合作而闻名。

Under this collaboration, the firm will develop a strategic brand name and identity for Polyrizon’s proprietary Capture and Contain™ (C&C) hydrogel technology, an innovative intranasal spray formulation designed to create a protective biological barrier against allergens and viruses. This initiative marks a crucial step forward in Polyrizon's pathway to commercialize its technology and effectively communicate its unique benefits to the market..

在此合作下，该公司将为 PolyRizon 专有的捕获与包含™（C&C）水凝胶技术开发一个战略品牌名称和形象。这种创新的鼻喷雾剂配方旨在创建一个对抗过敏原和病毒的保护性生物屏障。此举标志着 PolyRizon 在将其技术商业化的道路上迈出了关键一步，并有效向市场传达其独特优势。

The scope of the engagement will encompass comprehensive trademark screening and linguistic evaluations across the U.S. and European markets, ensuring optimal brand viability and compliance with global regulatory requirements.

此次合作的范围将涵盖在美国和欧洲市场进行全面的商标筛选和语言评估，以确保品牌最佳的可行性和符合全球监管要求。

Polyrizon anticipates completing the brand development process in alignment with its ongoing clinical and regulatory milestones.

Polyrizon预计将在与其正在进行的临床和监管里程碑保持一致的情况下完成品牌开发过程。

About Polyrizon Ltd.

关于Polyrizon有限公司。

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue.

Polyrizon是一家处于开发阶段的生物技术公司，专注于开发以鼻喷雾形式递送的创新型医疗设备水凝胶，该水凝胶在鼻腔内形成一层薄薄的水凝胶基屏障，可提供针对病毒和过敏原接触鼻上皮组织的防护屏障。

Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs.

Polyrizon 的专有捕获与包含 TM（C&C）水凝胶技术，由天然存在的构建块混合而成，以鼻喷雾的形式递送，并可能在鼻腔内形成一个带有薄屏蔽屏障的“生物面具”。Polyrizon 正在进一步开发我们 C&C 水凝胶技术的某些方面，例如用于鼻内药物递送的生物粘附性和在鼻沉积部位的延长滞留时间。

Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit .

Polyrizon 提及其另一项处于早期临床前开发阶段的额外技术，该技术专注于活性药物成分（API）的鼻腔递送，称为捕获与靶向™（Trap and Target™，或 T&T）。欲了解更多信息，请访问。

https://polyrizon-biotech.com

https://polyrizon-biotech.com

.

。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》及其他证券法意义上的“前瞻性声明”。诸如“预期”、“预计”、“打算”、“计划”、“相信”、“寻求”、“估计”以及类似表述或这些词语的变化均旨在识别前瞻性声明。

For example, the Company is using forward-looking statements when it discusses its pathway to commercialize its technology and effectively communicate its unique benefits to the market and its anticipation of completing the brand development process in alignment with its ongoing clinical and regulatory milestones.

例如，当公司讨论其技术商业化的途径、有效向市场传达其独特优势，以及预期完成与正在进行的临床和监管里程碑相一致的品牌开发过程时，公司正在使用前瞻性陈述。

Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements.

前瞻性陈述并非历史事实，而是基于管理层当前的预期、信念和预测，其中许多本质上具有不确定性。这些预期、信念和预测是出于善意表达的。然而，无法保证管理层的预期、信念和预测将会实现，实际结果可能与前瞻性陈述中表达或暗示的内容存在重大差异。

Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC.

前瞻性声明受风险和不确定性的影响，可能导致实际表现或结果与前瞻性声明中表达的内容有重大差异。有关影响公司的风险和不确定性的更详细描述，请参阅公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司于2025年3月11日向SEC提交的年度报告以及随后向SEC提交的文件中详述的风险。

Forward-looking statements speak only as of the date the statements are made. The Company .

前瞻性声明仅在声明发布之日有效。公司。

Contact:

联系：

IR@polyrizon-biotech.com

IR@polyrizon-biotech.com